HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progenitor cell transplantation for chronic myelogenous leukemia.

Abstract
Chronic myelogenous leukemia (CML), a myeloproliferative disorder characterized by the clonal proliferation of a hematopoietic stem cell, is a malignancy for which allogeneic bone marrow transplantation (BMT), when available, constitutes a mainstay of treatment. Several clinical considerations, especially the patient's age, influence the availability and likely outcome of BMT for patients with CML. Recent advances in nontransplant treatments for CML, notably interferon-alpha, have made the decision about the implementation and timing of BMT in CML more complex. Areas of active investigation include transplantation from a matched unrelated donor (MUD) and autologous BMT.
AuthorsT P Szatrowski
JournalSeminars in oncology (Semin Oncol) Vol. 26 Issue 1 Pg. 62-6 (Feb 1999) ISSN: 0093-7754 [Print] United States
PMID10073562 (Publication Type: Journal Article, Review)
Chemical References
  • HLA Antigens
Topics
  • Clinical Trials as Topic
  • HLA Antigens
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (surgery)
  • Transplantation, Autologous
  • Transplantation, Isogeneic
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: